Asian approvals hit snag; Micrus slashes targets
This article was originally published in Clinica
Executive Summary
Micrus Endovascular, a company that manufactures devices for treating brain aneurysms, is now expecting fiscal 2008 revenue to be up to $20m lower than forecast, as it braces itself for the impact of potential product approval delays in Asia.